Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
CONCLUSIONS: This retrospective study in an actual practice setting showed that CANA patients were generally as likely as GLP-1 patients to achieve HbA1c, weight, and blood pressure thresholds and to maintain glycemic control while being less likely to discontinue treatment and/or have a new antihyperglycemic prescribed.
PMID: 29557199 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Canagliflozin | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Electronic Medical Records (EMR) | Endocrinology | Invokana | Research | Study | Weight Loss